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Monoclonal antibodyrus has been implicated as a target for vaccines with broad cross-strain coverage.
Studies in small animal models have shown that antibody responses induced by 23-mer M2 peptide vaccines
can provide protection against inﬂuenza A virus challenge. To study antiviral mechanisms of Merck M2-
OMPC conjugate vaccine, we generated and characterized four M2 peptide-speciﬁc monoclonal antibodies
(mAbs). Here we demonstrated that the protection by our M2 mAbs is independent of NK-mediated effector
functions in mice. The protective mAbs preferentially bind to M2 multimers composed of two or more M2
peptides in parallel orientation. Our ﬁndings indicate that the protective M2 Ab prefer to bind to epitopes
located within the N-terminal 10 amino acids of the M2 peptide, and the epitopes are likely formed by two
M2 peptides in parallel orientation. The implications of these results in antiviral mechanisms of immune
responses induced by M2 vaccines are discussed.
© 2008 Elsevier Inc. All rights reserved.IntroductionWe and others have shown that vaccine-induced antibody
responses against M2 protein, a viral ion channel protein, can provide
protection against inﬂuenza A virus challenges in mouse and ferret
models (Fan et al., 2004; Frace et al., 1999; Liu and Chen, 2005;
Mozdzanowska et al., 2003; Neirynck et al., 1999; Okuda et al., 2001;
Slepushkin et al., 1995). M2 protein is a minor viral protein of
inﬂuenza Avirus, and is transcribed fromviral RNA segment 7 through
alternative splicing (Lamb et al., 1985). It is an integral membrane
protein 97 amino acids long, with an ectodomain of 23 amino acids, a
transmembrane segment of 19 and a cytoplasmic domain of 54 amino
acids. M2 protein is expressed abundantly on the surfaces of inﬂuenza
A virus-infected cells but is incorporated only in limited copy number
in mature virions (Lamb et al., 1985; Zebedee and Lamb, 1988). M2
protein exists as a membrane-bound homotetramer, stabilized by
intermolecular disulﬁde bonds formed between Cys residues at
positions 17 or 19 (Holsinger and Lamb, 1991). As a viral ion channel
with a proton transport function, M2 is essential for regulating pH to
release viral particles from endosomes, and also plays a role in virion
maturation in the trans-Golgi (Fischer and Sansom, 2002; Pinto et al.,
1997, 1992). The structure of the M2 transmembrane region in
complex with an antiviral agent, Amantadine, was recently deter-WP16-204 Sumneytown Pike
).
l rights reserved.mined to be four alpha helical bundles, highlighting its antiviral
mechanism of blocking or interfering with M2 ion channel function
(Schnell and Chou, 2008; Stouffer et al., 2008).
The concept of M2 as a vaccine antigen was based on early studies
of a monoclonal Ab (mAb), 14C2, developed 20 years ago in Robert
Lamb's laboratory (Treanor et al., 1990; Zebedee and Lamb, 1988,
1989). The presence of 14C2 inhibited viral replication in culture by
reducing plaque sizes against certain inﬂuenza A virus strains
(Zebedee and Lamb, 1988). The variant strains resistant to this mAb
in vitro contained mutations in M1 regions when compared to the
susceptible strains, raising the possibility that 14C2-mediated anti-
viral activity was related with interference of M1 and M2 interaction
during viral particle assembly and maturation (Zebedee and Lamb,
1989). In addition, surface expression of M2 was reduced in virus-
infected cells in the presence of 14C2 and the release of viral particles
was inhibited (Hughey et al., 1995). Furthermore, in vivo adoptive
transfer of 14C2 ascites in naïve mice can reduce viral titers in mouse
lungs sampled on days 3 and 4 post-challenge with inﬂuenza A virus
(Treanor et al., 1990). Several other M2 mAbs recently reported could
also confer protection when adoptively transferred in naïve mice
(Liuet et al., 2004; Zharikova et al., 2005). These mAbs were all
mapped to an immunodominant region located from residues 6 to 13
of M2 ectodomain.
Several M2 peptide vaccines are under early clinical evaluation. All
these vaccines showed promising degrees of protection against
inﬂuenza virus challenge in small animals (Fan et al., 2004; Neirynck
et al., 1999). However, their clinical efﬁcacy and, more importantly,
Fig. 1. Generation of four M2mAbs. IgG of four mAbs to M2 ectodomainwere titrated in
ELISA against the synthetic 23-mer M2 peptide (SLLTEVETPIRNEWGCRCNDSSD) coated
on the plate. The isotypes of four mAbs were determined.
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our understanding of antiviral mechanisms by Merck M2-OMPC
conjugate vaccine (Fan et al., 2004), we generated a panel of fourmAbs
speciﬁcally to the M2 protein ectodomain. We demonstrate here that
adoptively transferring two of these mAbs as puriﬁed IgGs can confer
protection against lethal challenge with inﬂuenza A virus in mice, and
the protection is independent of NK-mediated effector functions. We
further characterize the epitopes and substrate binding properties of
these mAbs, and show that the two protective mAbs bind to a set of
epitopes located within the N-terminal 10 amino acids of M2 peptide,
distinct from other anti-M2 mAbs previously reported. Moreover, the
two protective mAbs preferentially bind to epitopes formed by
multimeric M2 peptides. The relevance of our ﬁndings to antiviral
immune responses induced by M2-based vaccines is discussed.Fig. 2. Protection against lethal inﬂuenza virus challenge by adoptive transfer of M2 mAb in m
intraperitoneally. Control mice received nothing (naïve group) or PBS. Mice were challenged
was monitored for 21 days. The data shown are representative of two experiments.Results
Generation of M2-speciﬁc mAb
To generate mAbs speciﬁc for the M2 ectodomain, we immunized
BALB/c mice with 23-mer M2 peptide (residues 2 to 24) conjugated
at its C-terminus to a carrier protein, OMPC (Fan et al., 2004). A panel
of four M2 mAb hybridoma clones was identiﬁed through screening
of immune hybridoma clones using standard techniques. The
puriﬁed IgG from four hybridoma clones (L18, S1, P6, and O19)
were conﬁrmed for binding to M2 peptide in a quantitative ELISA
(Fig. 1). Isotypes of L18, S1 and P6 were determined to be IgG1κ and
O19 to be IgG2aκ.
Antiviral activity of M2 mAb
An extensively studied M2 mAb, 14C2, restricts viral replication in
culture as demonstrated by reduced viral plaque sizes (Zebedee and
Lamb, 1988). However, this antiviral effect occurred only against
certain strains, such as A/Udorn/72 and A/HK/68, but not against A/
PR/8/34 and A/WSN/33. To evaluate antiviral potentials of our M2
mAbs, we tested them against inﬂuenza A viruses A/HK/68 and A/
WSN/33 in 3-day plaque assays. No plaque size reduction was
observed with these M2 mAbs even at concentrations as high as
50 μg/ml (data not shown). Since it has been reported that mAb 14C2
can restrict viral release (Hughey et al., 1995), we next evaluated
whether our mAbs could delay or alter the viral growth kinetics. We
found that the presence of these mAbs had little effect on growth
kinetics of A/HK/68 at low MOIs of 0.1 and 0.01 (data not shown).
Thus, we concluded that these mAbs have no or negligible antiviral
activity in vitro, similar to M2 peptide immune sera previously tested
(Fan et al., 2004).
To evaluate their antiviral potentials in vivo, we adoptively
transferred the mAbs in titrated quantity in groups of 10 naïve Balb/
c mice (Fig. 2). The mice were challenged intranasally with aice. Groups of 10 naïve BALB/c mice received titrated amounts of puriﬁed M2 mAb IgG
intranasally about 2–4 h later with an LD90 dose of A/HK/68 reassortant virus. Mortality
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transfer of IgG. Naïve mice receiving no treatment and the mice
receiving PBS suffered 90% and 100% mortality, respectively, as
expected in this model. Protection against mortality was noted for
the groups receiving 2mg and 0.2mg ofmAb L18 or O19 IgG, while the
transfer of IgGs of mAb P6 and mAb S1 provided no protection in all
dose groups. The effective doses of adoptively transferred IgGs to
provide 50% protection (Protection ED50) in this experiment were
determined to be 63 μg for L18 and 47 μg for O19 using the Reed and
Muench method.
Because M2 protein is abundantly expressed on the cell surfaces
of viral infected cells, it has been speculated that the protection of
M2 vaccines is mainly mediated through ADCC by NK cells
(Jegerlehner et al., 2004). To evaluate the role of NK cells in
protection by anti-M2 mAbs, we conducted a challenge experiment
in C57Bl/6 mice, a mouse strain that can be effectively depleted of
NK cells using a well-established regimen with NK1.1 speciﬁc mAb
PK136 (Seaman et al., 1987). In a pilot experiment, we treated mice
with PK136 at day −3 and −1, and assessed depletion efﬁciency on
day 0 using peripheral blood samples collected from mouse tail
veins. We conﬁrmed that such a regimen can remove more than 90%
NK1.1 positive cells in peripheral blood in ﬂow cytometry analysis
(data not shown). Groups of 10 C57Bl/6 mice with or without NK
cell depletion were adoptively transferred with 1 mg of puriﬁed IgG
of L18, O19 or S1, and then challenged about 2–4 h later with A/HK/
68 virus. The groups with NK cell depletion were treated with PK136
at day 4 and day 7 again to maintain NK depletion. As shown in Fig.
3, protection against lethal challenge in the groups receiving L18 or
O19 mAb was conﬁrmed and the protection was not affected by NK
cell depletion. Administration of S1 mAb provided marginal
protection in this experiment, and this marginal protection was
not affected by depletion of NK cells. Thus, we concluded that the
protection by the M2 mAbs in mice was not dependent on NK cells-
mediated ADCC.Fig. 3. Effects of NK cell depletion on protection by adoptive transfer of M2mAb in mice. Grou
L18, O19 or S1 mAbs, and were challenged with LD90 dose of A/HK/68 reassortant virus intran
PK136 mAb (NK1.1 mAb) intraperitoneally on day −3, −1, 4 and 7 of challenge, and this NK d
blood collected after 2 PK136 mAb treatment (data not shown). Mortality and morbidity (wM2 mAb binding to M2 expressed on viral infected cells or M2
incorporated in virions
We analyzed the immunological properties of our mAbs which
could underlie their protective efﬁcacy in the mouse challenge model.
First, we determined by ﬂow cytometry that L18, O19 and S1 mAbs,
but not P6 mAb, could bind to M2 expressed on MDCK cells infected
with A/HK/68 virus (Fig. 4). We then tested if thesemAbs could bind to
M2 protein on inﬂuenza A virus by electron microscopy of immuno-
gold-stained virions. Aliquots of A/HK/68 virus were ﬁxed on copper
mesh grids and incubated with either M2 mAb IgG or isotype control
IgG, followed by a goat-anti-mouse IgG secondary Ab labeled with
colloidal gold (Fig. 5). With an isotype-matched control IgG, very few
gold particles were observed in the multiple ﬁelds examined, and
none were found to be associated with viral particles. M2 mAb L18-,
O19-, and S1-stained samples showed speciﬁc binding shown by
colloidal gold particles in clusters associated with viral particles (Fig.
5). L18-, O19-, and S1-speciﬁc staining was identiﬁed on approxi-
mately 60%, 65%, and 40% of viral particles, respectively, in the
multiple ﬁelds examined. P6 reacted poorly with viral particles and
there were only approximately 5% of viral particles seen with gold
particle staining. These data conﬁrmed that L18, O19 and S1 mAbs can
effectively recognize native M2 protein presented either on the
surface of virus infected cells or incorporated in virions.
Epitope mapping with truncated and Ala substitution peptides
To further characterize these mAbs, we deﬁned their core epitopes
using a set of synthetic M2 peptides either progressively truncated or
serially substituted with alanine. The reactivity of the mAbs to these
substrate peptides and the core epitopes were determined by ELISA
and are summarized in Fig. 6. We were not successful in mapping the
core epitope of mAb P6, as it failed to react with any truncated or Ala-
substituted peptide, even at a high concentration of 1 μg/ml. Thisps of 10 C57Bl/6 mice were administrated intraperitoneally with 1 mg IgG per mouse of
asally. NK cell depletion was accomplished and maintained by administration of 100 μg
epletion regimen was conﬁrmed in a pilot experiment by ﬂow cytometry of peripheral
eight loss, data not shown) were monitored for 21 days.
Fig. 4. Staining of inﬂuenza A virus-infected cells with M2 mAbs by ﬂow cytometry. MDCK cells, infected with A/HK/68 reassortant virus at an MOI of 1 for 3 h, were trypsinized and
stained with a mixture of isotype-matched control mouse IgG (IgG1 and IgG2a) or M2 mAb IgG at 1 μg/ml. The cells were further stained with goat-anti-mouse IgG conjugated with
FITC (BD) and ﬁxed with 10% paraformaldehyde. The cells were analyzed on BD FACSCaliber™.
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compared to the other three mAbs. Two protective mAbs, L18 and
O19, recognized epitopes located toward the N-terminal 10 amino
acids of the M2 peptide, while the weakly protective mAb S1
recognized an epitope located within residues 7–13 of the M2
peptide. Thus, we showed that the two protective mAbs bind to a set
of epitopes different from those M2 mAbs which were previously
reported (Liu, Zou, and Chen, 2004; Zebedee and Lamb, 1988;
Zharikova et al., 2005).Fig. 5. Immuno-gold staining of inﬂuenza A virus with M2 mAb by electron microscopy. A
incubated with M2mAb or a mixture of isotype control IgG1 and IgG2a. The grids were stained
L18, O19 and S1 to viral particles are shown in the respective panels as cluster of dark partiSubstrate binding preference
It was noted that O19 mAb binds poorly to M2 peptide coated on
plates in ELISA (Fig. 1), yet it had antiviral activity comparable to L18
mAb in adoptive transfer experiments. The mapping experiments
indicated that O19 recognized an epitope located at the N-terminus of
M2 peptide. We wanted to test the possibility that O19 mAb might
prefer to bind M2 peptide in a speciﬁc orientationwith its N-terminus
exposed. Accordingly, we generated a synthetic peptide, designatedliquots of A/HK/68 reassortant virus were applied to 300 mesh copper grids and then
with goat-anti-mouse IgG labeled with colloidal gold particles. The speciﬁc bindings of
cles. The bars in each panel represent the length of 100 nm.
Fig. 6.Mapping the core epitopes of M2mAbs. Synthetic peptides corresponding to N- or C-terminal truncations or C-terminal alanine substitutionwere tested as substrates for mAb
reactivity in ELISA (panel A). Peptides were coated at 4 μg/ml on NUNC plates, and mAbs were incubated at 1 μg/ml concentration. A positive reactivity is deﬁned as the OD450 nm
value greater than two times that of negative control samples. The deduced core epitopes for the mAbs are summarized in panel B.
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leucine zipper sequence derived from yeast transcription factor GCN4.
The leucine zipper sequence has been demonstrated to form a stable
tetrameric coiled-coil structure (Harbury et al., 1993). We hypothe-Fig. 7. Substrate preference by M2 mAb in ELISA. M2/GCN4 was a synthetic pept
(PLMKQIEDKLEEILSKLYHIENELARIKKLLGER), a sequence identiﬁed to form a coiled-coil t
peptide at its C-terminus to BSA. M2 peptide and other M2 substrates were coated on ELISA p
a ﬁxed concentration (100 ng/ml).sized that this structure would present M2 peptide in parallel as a
homo-tetramer, similar to the 4-helix bundle structure deﬁned for
ectodomain and transmembrane regions of M2 protein (Schnell and
Chou, 2008; Stouffer et al., 2008). We also generated M2 peptide-BSAide formed with M2 peptide and a leucine zipper sequence from yeast GCN4
etramer (Harbury et al., 1993). M2-BSA conjugate was prepared by conjugating M2
late at a deﬁnedM2molar concentration. M2mAbs were tested with these substrates at
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Materials and methods). All substrates were diluted to equal molar
concentrations of M2 peptide content and then coated in titrations
onto ELISA plates. The mAbs at ﬁxed concentration was tested for itsFig. 8. Solution-phase binding ofM2mAb toM2 peptide versusM2 dimer peptide. Fixed
amounts of IgG (L18, O19 or S1 mAb) were incubated with titrated amounts of M2
peptide or M2 dimer peptide in solution overnight to allow the antibody–antigen
interaction to reach equilibrium. The amount of free IgG at equilibrium was measured
by a quantitative ELISA, and the amount of IgG bound to M2 peptide or M2 dimer
peptide at equilibriumwas calculated based on differences of input IgG and free IgG. The
percentages of input IgG bound to M2 peptide or to M2 dimer peptide at equilibrium
were plotted against concentrations of M2 peptide or M2 dimer. Binding EC50 values
were derived from a 4-parameter ﬁtting analysis and represent the concentrations of
M2 peptide or M2 dimer peptide needed to capture 50% of input IgG.reactivity to these substrates. The results in Fig. 7 show that L18 and S1
mAb bound to all substrates tested but with slightly lower binding to
M2/GCN4 peptide. As previously shown, O19mAb bound poorly to M2
peptide coated randomly on the plate, but interestingly, it reacted
efﬁciently to M2/GCN4 peptide or M2 peptide-BSA conjugate. P6 mAb
failed to bind any substrate other than M2 peptide coated onto the
plate at high concentration. This ﬁnding, combined with epitope
mapping experiments described above, suggested that O19 mAb
recognized an epitope located at the extreme N-terminus of M2
peptide and preferred M2 peptides presented in a parallel orientation.
This result also raised the possibility that O19 preferentially interacts
with an epitope formed by two or more M2 peptides in parallel
orientation.
M2 peptide versus M2 dimer peptide
We synthesized an M2 dimer peptide in which two M2 peptides
were covalently linked at position 17 of Cys (see Materials and
methods), mimicking the intermolecular disulﬁde bonds formed
between 2 adjacent M2 peptides at position 17 (Holsinger and
Lamb, 1991). Binding of IgG to small peptides coated on ELISA plates
may not be ideal because hydrophobic interactions for peptide coating
on plates could constrain peptide conformation, thus interfering with
antibody–antigen interaction. Also, potentially not all faces of small
peptides coated on the plate are accessible to IgG, thus limiting or
distorting epitopes optimal for antibody interaction. To address these
concerns, we designed a solution binding assay for antibody–antigen
interaction where mAb IgG could interact with M2 peptides without
physical constraints. In this assay, a ﬁxed concentration (0.2 nM) of IgG
was incubated with titrated M2 peptide or with M2 dimer in solution
overnight to allow the antibody–antigen interaction to reach
equilibrium. The amount of free IgG at equilibriumwas thenmeasured
in a quantitative ELISA, and the percent of IgG bound to M2 peptide or
to M2 dimer as an immune complex at equilibrium was calculated
based on the difference of input IgG and free IgG. The percent bound
IgG was plotted against concentrations of M2 peptide or M2 dimer
(Fig. 8). Results showed that L18 could interact with both M2 peptide
and M2 dimer in solution, and that the percent IgG bound at
equilibrium was inversely correlated with M2 peptide and M2 dimer
concentrations. Interestingly, L18 mAb interacted with M2 dimer
more efﬁciently than with M2 peptide. O19 mAb failed to bind M2
peptide in solution, but could bind toM2 dimerwith high efﬁciency. S1
mAb could bind to bothM2 peptide andM2 dimerwith approximately
equal efﬁciency. Using a 4-parameter ﬁtting model, we calculated the
substrate (M2 peptide or M2 dimer) concentration needed to capture
50% of input IgG (Binding EC50) at equilibrium; a lower Binding EC50
values indicated a more favorable (higher afﬁnity) antibody–antigen
interaction in solution. Results in Fig. 8 showed that L18mAb bound to
M2 dimerwith a Binding EC50 of 0.09 nMversus toM2 peptide Binding
EC50 of 1.47 nM, which means that the concentration of M2 peptide
needed to occupy 50% of input IgG was 16-fold higher than that of M2
dimer. The Binding EC50 for O19mAb binding toM2 dimerwas close to
that of L18mAb toM2 dimer, 0.11 nM and 0.09 nM, respectively, while
S1 mAb bound to both M2 peptide and M2 dimer approximately
equally, 1.49 nM and 4.23 nM, respectively, with a Binding EC50 similar
to that of L18 mAb to M2 peptide (1.47 nM). These results suggested
that both L18 and O19 mAbs preferred speciﬁc epitopes present in the
M2 dimer, while S1 mAb recognized a linear epitope present in both
the M2 peptide and the M2 dimer.
Discussion
Although the M2 protein is under evaluation in clinical trials as a
target for inﬂuenza vaccines with broad cross-strain coverage, an
understanding of the antiviral mechanisms of Ab responses to the M2
ectodomain remain elusive. We report here a panel of four M2 mAbs
224 T.-M. Fu et al. / Virology 385 (2009) 218–226generated from mice immunized with M2 peptide-OMPC conjugates.
The antiviral efﬁcacy could be demonstrated in mice by adoptive
transfer of two mAbs, L18 or O19, but only marginally or not at all by
the two other mAbs, S1 and P6. Our characterizations of these
antibodies revealed that the core epitopes of the two protective mAbs
L18 and O19 were mapped to the N-terminal 10 residues of M2
peptide, while the non-protective S1 mAb recognized an epitope
located from residues 7–13, overlappingwith the epitope of mAb 14C2
(Zebedee and Lamb, 1988) and other M2 mAbs reported recently (Liu
et al., 2004; Zharikova et al., 2005). Additionally, both protectivemAbs
L18 and O19 showed a preference to interact with M2 dimer over
monomer M2 peptide, suggesting that bothmAbs bind to the epitopes
of a speciﬁc conformation present in multimeric M2 peptide in
parallel orientation.
We were unable to demonstrate any in vitro antiviral activity with
these mAbs, using the plaque size reduction assay published
previously for mAb 14C2 (Zebedee and Lamb, 1988). Also, these
mAbs showed no effect on viral growth kinetics. It should be noted
that, in the study by Zebedee et al. antiviral activity by mAb 14C2
could be demonstrated only against certain viral strains, including A/
Udorn/72 and A/HK/68 (Zebedee and Lamb, 1988). Thus, the inability
to demonstrate in vitro antiviral activity with our M2 mAb, with mAb
14C2 as control, against the A/HK/68 viral isolate may reﬂect some
subtle virological divergences of this strain accumulated through
years of in vitro passages. Nonetheless, adoptive transfer can confer
protection against lethal challenge with inﬂuenza virus in mice with
L18 and O19 mAbs, but not or only marginally with P6 and S1 mAbs,
respectively. It should be noted that protection inmicewithmAb 14C2
in our hands could only be accomplished as ascites ﬂuid, not as
puriﬁed IgG (Liang et al, unpublished observation). Thus, we
conducted our evaluation of these mAbs as puriﬁed IgGs which
allowed us to compare these mAbs quantitatively. Protective efﬁcacy
of L18 and O19 mAb, i.e., amount of IgG needed to provide 50%
protection (Protection ED50) in our mouse challenge model, could be
estimated from the survival data in Fig. 2, using Reed and Muench
method. The Protection ED50 values for L18 and O19 mAbs were thus
calculated as 63 and 47 μg, respectively.
A recent study indicated that NK cell-mediated ADCC is a
protective mechanism induced by M2 vaccines in mice, using anti-
asialo-GM1 as a NK cell depletion agent (Jegerlehner et al., 2004).
Our data, however, offer an alternative view. First, the protective L18
mAb is IgG1, not isotypes such as IgG2a or IgG2b, previously shown to
be more important for mediation of ADCC in mice (Denkers et al.,
1985). Second, our data showed that speciﬁc depletion of NK cells in
mice by a mAb targeted to NK1.1 had no effect on protection by
adoptive transfer of either L18 (isotype IgG1) or O19 (isotype IgG2a)
mAbs. Third, the protection by L18 mAb in mice could only be
effective if adoptively transferred on the day of viral challenge, but
not on day 2 or day 4 of viral challenge (T-M. Fu et al, unpublished
observation). This result suggested that L18 mAb was less effective in
protecting against mortality in mice once the viral infection was
established. Thus, our data argue for a different mechanism by M2
vaccine-induced immune protection other than NK cell-mediated
ADCC. It is difﬁcult to reconcile our ﬁnding with the previous study
on the role of NK cells in the protection in mice, but our conclusion
was drawn from the experiments conducted with the two puriﬁed
M2 mAbs, one IgG1 and the other IgG2a, in contrast to the other study
with the vaccinated mouse sera (Jegerlehner et al., 2004). We suggest
that there may be an unappreciated factor present in whole sera from
vaccinated mice.
Our study further revealed that the two mAbs with antiviral
activity, L18 and O19, reacted to M2 peptide differently from S1 mAb.
First, the core epitopes for L18 and O19 mAbs are mapped to the N-
terminus of M2 peptide, spanning from residues 2 to 10, while that of
S1 mAb is located from residues 7 to 13. Second, O19 mAb has a more
stringent binding preference for multimeric M2 peptide in parallelorientation, as in M2/GCN4 peptide or M2-BSA conjugate. O19 reacted
poorly with singular M2 peptide, either randomly coated on the plate
in ELISA (Figs. 1 and 7) or in solution (Fig. 8), but it appeared to
recognize native M2 protein on viral infected cells or incorporated in
inﬂuenza virions (Figs. 4 and 5) or the surface of virus-infected MDCK
cells as efﬁciently as L18 mAb (data not shown). Third, both protective
mAbs, L18 and O19, bind to M2 dimer in solution with much higher
afﬁnity than to M2 monomer peptide, while S1 mAb showed no such
preferential binding in solution (Fig. 8). We have not yet conﬁrmed
deduced dissociation constants, i.e., KD, of these interactions by
surface plasmon resonance analysis, thus we elect to highlight the
substrate preference of these mAbs with their respective Binding EC50
values (Fig. 8). Our data indicated that the protective mAbs, L18 and
O19, recognized more complex epitopes better presented by the M2
dimer peptide, while the non protective S1 mAb interacted with M2
peptide and M2 dimer indiscriminately and likely recognized a linear
epitope.
The transmembrane region of M2 protein forms a 4-helix bundle
structure with residues 37 (His) pointed outward as a proton sensor,
and 41 (Trp) pointed inward as potential gate for M2 ion channel
function (Pinto et al., 1997; Tang et al., 2002; Tian et al., 2003). Recent
studies have solved the structure of the M2 transmembrane region (4-
helix bundle), in complex with an antiviral agent, Amantadine, and
conﬁrmed its antiviral mechanism in blocking or interfering with M2
ion channel function (Schnell and Chou, 2008; Stouffer et al., 2008).
No structural feature of theM2 ectodomain has been reported, but our
data indicated that two protective mAbs preferentially react to
epitopes composed of two copies of M2 peptides. Whether the
binding of L18 and O19 mAbs to more complex epitopes of M2 protein
interfere with M2 ion channel function remain to be determined. One
intriguing possibility is that the bound mAb could constrain M2
protein movement, e.g., helical rotation, in the 4-helix bundle that is
necessary for proton transport (Pinto et al., 1997; Schnell and Chou,
2008; Stouffer et al., 2008; Tang et al., 2002). In this regard, antibodies
binding to linear epitopes on M2 peptides, such as S1 mAb, would be
expected to be not as effective in constraining such M2 protein
movement and interfering in ion channel function as those binding to
the complex epitopes composed from two M2 peptides. Thus, it is
likely that the antiviral activity of M2 Abs in vivo is dependent upon
their ability to inhibit M2 ion channel functions. Because whether M2
ion channel function is needed to support several rounds of viral
replication in vitro is still a subject of debate (Watanabe et al, 2001;
Takeda et al, 2002), antiviral activities by our M2 mAbs may need
improved culture systems to demonstrate this effect. Nonetheless,
further characterizations on structural epitopes of L18 and O19 could
shed light on this hypothesis.
In summary, we reported a new class of M2 mAbs recognizing
epitopes located at N-terminal 10 residues of M2 peptide. Our
protective mAbs, L18 and O19, preferentially bind to the dimer or
multimeric M2 peptides, and they are different from other class of M2
mAbs, reported earlier (Liu et al., 2004; Zebedee and Lamb, 1988;
Zharikova et al., 2005) or in this study (S1 mAb), likely recognizing
linear epitopes located from residues 6 to 13 ofM2 peptide.We further
demonstrated that protection in mice by M2 mAb, L18 and O19, is not
dependent on NK-mediated effector function, contrary to a previous
report (Jegerlehner et al., 2004), but rather linked to the biochemical
natures of their epitopes. Our ﬁndings pose an interesting challenge as
how to design a more effective M2 peptide vaccine capable of eliciting
more L18- and O19-like Abs.
Materials and methods
Mice and inﬂuenza virus challenge model
Female Balb/c and C57Bl/6 mice 8 to 12 weeks-old were purchased
from Taconic Farm and housed at animal facilities of Merck Research
225T.-M. Fu et al. / Virology 385 (2009) 218–226Laboratories in accordance with the Guide for the Care and Use of
Laboratory Animals by National Research Council. All animals studies
described in this report were approved by the Merck Research
Laboratories Institutional Animal Care and Use Committee. The details
on the mouse challenge model with a mouse-adapted inﬂuenza A
virus have been described previously (Fan et al., 2004). The challenge
virus was genetically determined to be a reassortant virus between
strains of A/PR/8/34 (H1N1) and A/HK/68 (H3N2). The virus stocks,
propagated in allantoic ﬂuid of 10 day-old embryonated chicken eggs,
were titrated in groups of 10 mice to determine a challenge dose
causing 90%mortality (LD90) (Fan et al., 2004). Micewere anesthetized
with ketamine/xylazine and inoculated intranasally with 20 μl of virus
diluent. Survival and mouse body weight (average weight of
survivors) were monitored daily for 21 days.
For adoptive transfer experiments, mAb IgG was diluted to the
designed concentrations in PBS, and was administrated in 0.5 ml
intraperitoneally. Between 2 and 4 h later, the mice were anesthetized
and challenged as outlined above. For NK cell depletion, themicewere
treated with 100 μg PK136 mAb, a generous gift from Gloria Koo of
Memorial Sloan Kettering Cancer Center in NY (Seaman et al., 1987),
intraperitoneally on days −3 −1, 4 and 7 relative to inﬂuenza virus
challenge. The regimen was conﬁrmed in a pilot study for successful
depletion of NK cells fromperipheral blood samples collected from tail
veins by ﬂow cytometry.
Peptides, M2 peptide-conjugates, and Immunization
Synthetic peptides were prepared by standard t-Boc solid phase
synthesis in our laboratories or contracted to commercial vendors,
including SynPep, Inc. Dublin, CA, and Virolabs, Inc., Chantilly, VA. M2/
GCN4 peptide was composed of the M2 ectodomain (SLLTEVETPIR-
NEWGCRCNDSSD) and a modiﬁed leucine zipper sequence from yeast
transcription factor GCN4 (PLMKQIEDKLEEILSKLYHIENELARIKKLL-
GER), shown to preferentially form tetramers in solution (Harbury et
al., 1993). M2 dimer peptide was synthesized through two separate
peptides, M2.1 (SLLTEVETPIRNEWG-Asp-RSNDSSD) and M2.2 (SLLTE-
VETPIRNEWG-Dap-RSNDSSD), of which the amino acid Boc-Asp
(OFm) was incorporated at the position of Asp in M2.1, and the
amino acid Boc-1,3-L-Diaminopropionic acid (Fmoc) at the position of
Dap in M2.2. The covalent linking of M2.1 andM2.2 was accomplished
by ﬁrst treating an equal molar mixture of 2 peptidyl resins with 20%
piperidine/NMP to selectively remove OFm and Fmoc protecting
groups, and then with BOP/DIEA to promote formation of an
intermolecular amide bond between side chain of Asp in M2.1 and
Dap in M2.2. M2 dimer peptide was puriﬁed by reverse phase-HPLC.
All peptides were puriﬁed to greater than 80% purity, characterized by
HPLC and mass spectrometry.
The method for conjugation of M2 peptide with BSAwas based on
maleimide-thiol chemistry as previously describedwithmodiﬁcations
(Joyce et al., 2002). For BSA conjugations, maleimide-activated BSA
(Pierce) was mixed with M2(SRS)-Cys peptide at an equal molar ratio
of thiol to maleimide. The reaction was incubated for 15 h in the dark
at 4 °C. Residual maleimides were quenched with β-mercaptoethanol
and the unconjugated peptide and reagents were removed by dialysis.
Generation of mAb hybridomas
The procedure for generation of mAb hybridoma was modiﬁed
from standard protocols (Yokoyama, 2003). Brieﬂy, a female BALB/c
mouse of 4 to 10 weeks age was immunized intraperitoneally with
20 μg of M2 peptide conjugated with OMPC (Fan et al., 2004),
formulated with equal volume of complete Freund's adjuvant
(priming immunization, week 0), or incomplete Freund's adjuvant
(booting immunizations, weeks 2 and 4). The mouse was boosted
intravenously with 10 μg of M2 peptide diluted in 100 μl volume of
PBS, and 3 days later the spleen cells were isolated and fused withpartner cells, SP2/0myeloma cell line (ATCC), with polyethylene glycol
(Sigma Aldrich, St Louis, MO). The cells were plated at 50000 cells per
well in a 96-well ﬂat bottom plate and cultured at 37 °C with 5% CO2
for 10 to 14 days in 200 μl of HAT selection medium, which is
composed of ISCOV medium supplemented with 10% FBS, 1 μg/ml
Hybrimax (azaserine-hypoxanthine, Sigma Aldrich), 30% conditioned
media collected from SP2/0 cell culture. The culture supernatants
were removed around days 12 to 14 to screen for positive wells in
ELISA. The positive cultures were further cloned by two rounds of
limiting dilutions.
Enzyme-linked immunosorbent assay (ELISA)
For solid phase ELISA, 96-well NUNC Maxisorb plates were coated
with antigen substrates in 50 μl per well at a concentration of 4 μg/ml
in 50 mM bicarbonate buffer, pH 9.6. The plates were incubated at 4 °C
over night. Plates were washed with phosphate buffered saline (PBS)
with 0.05% Tween-20 (PBST) and blocked with PBST supplemented
with 3% nonfat dry milk for 2 h at ambient temperature with gentle
rocking. 100 μl of serial diluted samples were added to each well in
duplicates, and the plates were incubated at ambient temperature for
1–2 h with rocking. After six washes with PBST, 50 μl per well of
diluted HRP-conjugated secondary Ab in PBST/milk was added (goat-
anti-mouse IgG, Jackson Laboratories, Bar Harbor, ME). The plates
were incubated at ambient temperature for 1 h with rocking. Plates
were washed three times and colorimetric reactions were accom-
plished with adding 100 μl per well of TMB substrate (Virolabs,
Chantilly, VA). After 5 to 10min incubation at room temperature in the
dark, the reaction was stopped by adding 100 μl of 1N H2SO4 per well
and colorimetric reactions were read at 450 nm for absorbance on an
ELISA plate reader.
For the solution phase binding assay, a ﬁxed concentration of IgG
(0.2 nM) was incubated with titrated concentrations of antigen
substrates in 200 μl volume in low binding plates. The plates were
incubated at ambient temperature overnight with gentle rocking to
allow the antibody–antigen complex to reach equilibrium. Concur-
rently, a set of capturing plates was prepared with M2 peptide coated
on NUNC Maxisorb plates as detailed above. The next day, 100 μl of
mixtures from solution phase binding reactions were transferred to
the capturing plates and incubated for 1 h with gentle rocking at
ambient temperature. This step would capture the unbound IgG (free
IgG) at equilibrium, and the immune complex (bound IgG) was
removed during subsequent washes. The free IgG bound to M2
peptide on the solid phase ELISA was quantiﬁed by a separate IgG
solid phase ELISA with mAb IgG titrated as a standard curve. The
percent of bound IgG was calculated by the formula: bound IgG=
(input IgG− free IgG) / input IgG. Binding EC50, deﬁned as the
concentration of antigen (M2 peptide or M2 dimer peptide) to
capture 50% of input IgG in solution, was calculated by 4-parameter
curve ﬁtting using the GraFit program (Erithacus Software, Horley
Surrey, UK). The standard errors for the Binding EC50 ﬁt parameter
were within 20%.
Staining of inﬂuenza A virus-infected cells with M2 mAb in ﬂow
cytometry
MDCK cells were infected by reassortant A/HK/68 at an MOI of 1
and incubated for 3 h at 37 °C. The cells were washed and trypsinized.
Aliquots of 1×106 cells were resuspended in 0.1 ml volume in PBS and
stained with either a mixture of isotype control mouse IgG1 and IgG2a,
or M2mAb IgG at 1 μg/ml on ice for 45min. The cells werewashed and
stained with 2 μl of goat-anti-mouse IgG-FITC (Becton Dickinson, BD)
in 0.1ml volume on ice for 30min. After washes, the cells were ﬁxed in
0.5 ml of 10% paraformaldehyde, and analyzed on a BD FACSCalibur™.
For each sample, at least 5000 events were collected and the datawere
analyzed with CellQuest program (BD).
226 T.-M. Fu et al. / Virology 385 (2009) 218–226Immunogold staining of inﬂuenza virus
Negative staining of inﬂuenza virus by immunogold labeling was
performed by Electron Microscopy Bioservices, LLC, Frederick, MD.
The stock of reassortant inﬂuenza A virus, A/HK/68, prepared from
embryonated eggs was diluted 1:3 in PBS and applied onto 300 mesh
copper grids, coated with formvar and carbon, pre-rinsed with PBS
with 0.01% BSA. The viral aliquot on the grids was air-dried and M2
mAb IgG was applied to the grids at 5 μg/ml. The grids were
thoroughly washed in PBS after 1 h, and then incubated with goat
anti-mouse IgG labeled with colloidal gold particles for 45 min. The
grids were washed with PBS and then with ultra-pure water, dried in
air. The samples were ﬁxed and stained with 2% phosphotungstic acid,
and examined in electron microscopy.
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